tulmimetostat   Click here for help

GtoPdb Ligand ID: 12615

Synonyms: compound 1 [US2022257577] | CPI 0209 | CPI-0209 | CPI0209
Compound class: Synthetic organic
Comment: Tulmimetostat (CPI-0209) is an orally bioavailable and selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2) [2], that was designed for anti-tumour potential. Expression of EZH2 in cancers is associated with progression, stem cell self-renewal, migration and angiogenesis.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 114.43
Molecular weight 562.12
XLogP 3.36
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC(=C(CNC(=O)C2=C(C)C3=C(C(=C2)Cl)O[C@](C)(C4CCC(CC4)N5CC(C5)OC)O3)C(=O)N1)SC
Isomeric SMILES CC1=CC(=C(C(=O)N1)CNC(=O)C2=CC(=C3C(=C2C)O[C@@](O3)(C)C4CCC(CC4)N5CC(C5)OC)Cl)SC
InChI InChI=1S/C28H36ClN3O5S/c1-15-10-23(38-5)21(27(34)31-15)12-30-26(33)20-11-22(29)25-24(16(20)2)36-28(3,37-25)17-6-8-18(9-7-17)32-13-19(14-32)35-4/h10-11,17-19H,6-9,12-14H2,1-5H3,(H,30,33)(H,31,34)/t17?,18?,28-/m1/s1
InChI Key CAAWBLRXQXMGHV-WOLMIXIISA-N
No information available.
Summary of Clinical Use Click here for help
Tulmimetostat (CPI-0209) has advanced to early stage clinical evaluation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04104776 A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2 Interventional Constellation Pharmaceuticals